phase readout
saveNCT07236099: Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
RECRUITINGupdated 6d ago
community read0 votes
Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.. Phase: PHASE2. Conditions: Prurigo Nodularis (PN)
view source ↗
comments(0)
5-min edit window · permanent after that